- Home
- EYEN vs BOLD Comparison
EYEN vs BOLD Comparison
Compare EYEN & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYEN
- BOLD
- Stock Information
- Founded
- EYEN 2014
- BOLD 2018
- Country
- EYEN United States
- BOLD United States
- Employees
- EYEN N/A
- BOLD N/A
- Industry
- EYEN Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- EYEN Health Care
- BOLD
- Exchange
- EYEN Nasdaq
- BOLD Nasdaq
- Market Cap
- EYEN 2.9M
- BOLD 30.3M
- IPO Year
- EYEN 2018
- BOLD 2024
- Fundamental
- Price
- EYEN N/A
- BOLD $1.07
- Analyst Decision
- EYEN Hold
- BOLD Buy
- Analyst Count
- EYEN 4
- BOLD 3
- Target Price
- EYEN $2.00
- BOLD $4.00
- AVG Volume (30 Days)
- EYEN 9.4M
- BOLD 363.5K
- Earning Date
- EYEN 08-11-2025
- BOLD 08-11-2025
- Dividend Yield
- EYEN N/A
- BOLD N/A
- EPS Growth
- EYEN N/A
- BOLD N/A
- EPS
- EYEN N/A
- BOLD N/A
- Revenue
- EYEN $67,063.00
- BOLD N/A
- Revenue This Year
- EYEN $7,680.45
- BOLD N/A
- Revenue Next Year
- EYEN $315.38
- BOLD N/A
- P/E Ratio
- EYEN N/A
- BOLD N/A
- Revenue Growth
- EYEN 663.82
- BOLD N/A
- 52 Week Low
- EYEN $0.85
- BOLD $1.00
- 52 Week High
- EYEN $124.80
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- EYEN 71.65
- BOLD N/A
- Support Level
- EYEN $7.50
- BOLD N/A
- Resistance Level
- EYEN $17.18
- BOLD N/A
- Average True Range (ATR)
- EYEN 3.10
- BOLD 0.00
- MACD
- EYEN 0.88
- BOLD 0.00
- Stochastic Oscillator
- EYEN 81.29
- BOLD 0.00
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.